The antibiotic tirandamycin (a 3-acyltetramic acid structurally related to streptolydigin) specifically inhibits transcription by interfering with the function of bacterial ribonucleic acid polymerase. Ribonucleic acid polymerases from rat liver nuclei are -not subject to tirandamycin inhibition. Qualitatively, the mode of action of the antibiotic is identical to that of streptolydigin in inhibiting chain initiation as well as chain elongation during the transcriptional process. However, tirandamycin is approximately 40 times less potent than streptolydigin. The structures of the 3-acyl groups of the two acyltetramic acid antibiotics tirandamycin and streptolydigin differ only slightly in the degree of oxidation of the terminal dioxabicyclo(3. 1)nonane system and possess the same stereochemistry (D. J. Duchamp, A. R. Branfman, A. C. Button, and K. L. Rinehart, 1973 ). More significantly, major differences occur at the 1 and 5 positions of the tetramic acids. Tirandamycin contains no substituents; streptolydigin contains a substituted acetamide function at position 5 and a sugar moiety at position 1. The lack of substituents at the 1 and 5 positions of the tetramic acid portion in tirandamycin is probably responsible for the reduced biopotency oftirandamycin as compared with streptolydigin.
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Tirandamycin, a new antibacterial agent, was isolated from the culture broth of Streptomyces tirandis sp. nov. (6; 0. K. Sebek and C. E. Meyer, U.S. Patent 3, 671, 628, 1972) . The compound was crystallized in the form of its sodium salt, which has a molecular weight of 439 .
Structural studies indicated that tirandamycin is a 3-acyltetramic acid related to streptolydigin (5) . The structural formulas for tirandamycin and streptolydigin are shown in Fig.   1 .
Chemically, tirandamycin differs from streptolydigin in minor functional groups within the acyl substituent at position 3 of the tetramic acid, but more significantly lacks the substituents present at position 1 (sugar) and position 5 (substituted acetamide) of the tetramic acid in streptolydigin.
Tirandamycin is a moderately active growth inhibitor of a variety of gram-positive bacteria in vitro, but has proved ineffective for the systemic treatment of experimental bacterial infections in mice.
Investigations of the mode of action of tirandamycin have shown that the agent is an inhibitor of bacterial ribonucleic acid (RNA) polymerase in a manner similar to streptolydigin. A preliminary account of these studies has been presented (7).
MATERIALS AND METHODS
RNA polymerase was isolated from Escherichia coli and assayed as described previously (7) . One RNA polymerase unit corresponds to 1 nmol of poly[d(A-T)I-directed adenosine 5'-triphosphate (ATP) incorporated per min.
The binding of E. coli RNA polymerase to template deoxyribonucleic acid (DNA) was assessed by the membrane (Millipore Corp.) filtration technique described by Jones and Berg (4) .
Mammalian RNA polymerase was isolated from rat liver nuclei by the procedures of Roeder and Rutter (9) . Fraction 4, containing the total nuclear RNA polymerases, was used as the enzyme source. Polymerase activity of this fraction was assayed as described by Chesterton and Green (2) .
E. coli '4C-labeled DNA (specific activity, 0.038 ,ACi/,ig) and [y-32P]guanosine 5'-triphosphate (GTP) (specific activity, 1.51 Ci/mmol) were purchased from Amersham/Searle.
RESULTS
Effect of tirandamycin on E. coli RNA polymerase. Tirandamycin effectively inhibited the de novo synthesis of RNA catalyzed by RNA polymerase (Fig. 2) . The concentration of antibiotic required to inhibit the reaction to the extent of 50% amounted to 0.8 mM, which suggests that tirandamycin is 
, 0.04 optical density at 260 nm units/ml; and polymerase, 0.5 U. Reactions were run at 30°C for 15 min and terminated by the addition of 3 ml ofcold 3.5% perchloric acid per tube. The acidinsoluble product was collected on 0.45-pm membrane filter paper disks, washed, and assayed for radioactivity. Effect of tirandamycin on the binding of polymerase to template DNA. The effect of tirandamycin on RNA polymerase binding to E. coli "4C-labeled DNA was assessed by the membrane (Millipore Corp.) filtration technique (4). This assay is based on the observation that template DNA-RNA polymerase complexes are retained by these filters, whereas enzyme-free DNA passes through.
In a first experiment the effect of tirandamycin on the formation of DNA-RNA polymerase complexes was assessed ( Table 3 ). The results show that tirandamycin did not interfere with the association of the complex, despite the presence of high concentrations of antibiotic. Congo red, a known inhibitor of this type of complex formation, proved highly inhibitory in our system.
If the DNA-RNA polymerase complex was allowed to form in the absence of tirandamycin and was then treated with the antibiotic, no dissociation of the preformed complex was observed (Table 4) . Hence, tirandamycin does not (Fig. 3) . The results show that in the mixtures containing rifamycin, RNA synthesis continued at a reduced rate for at least an additional 10 min after the addition of the antibiotic. Tirandamycin, on the other hand, caused immediate cessation of RNA synthesis upon the addition of the antibiotic. This indicates that tirandamycin, in contrast to rifamycin, inhibits RNA chain elongation as well as chain initiation. Interestingly, tenuazonic acid possesses essentially no antibacterial activity and is toxic in animals. In addition, it was reported that this acid acts as an inhibitor of protein synthesis in eucaryotic cells and cell-free systems (10) . It appeared appropriate to test the effect of tenuazonic acid in our cell-free, bacterial RNA polymerase system. The results assembled in Table 6 show that tenuazonic acid had no effect on the activity of bacterial RNA polymerase.
Effect of tirandamycin on mammalian RNA polymerase. The effect of tirandamycin on RNA polymerase of animal origin was studied in a test system derived from rat liver. RNA polymerase was purified from isolated rat liver nuclei to the step prior to diethylaminoethylcellulose chromatography, as described by Roeder and Rutter (9) . The preparation thus contained all of the nuclear polymerase species. Tirandamycin (or streptolydigin) did not inhibit RNA synthesis catalyzed by this enzyme preparation (Table 7) . Hence, tirandamycin specifically inhibits the catalytic function of the bacterial RNA polymerase species and does not impair the function of the animal polymerases.
DISCUSSION
The data presented demonstrate that tirandamycin acts as a specific inhibitor ofthe bacterial enzyme RNA polymerase. RNA polymerases of mammalian origin are not inhibited by the antibiotic. Tirandamycin does not prevent the binding of RNA polymerase to its template DNA. The processes of chain initiation and chain elongation are both subject to inhibition by tirandamycin.
Chemically, tirandamycin closely resembles the antibiotic streptolydigin and differs from the latter, especially in that it lacks the sugar substituent at the N position and the adjacent substitution at the 5 position of the tetramic acid. The mode of action of tirandamycin is qualitatively identical with that of streptolydigin. However, on a molar basis streptolydigin proves approximately 40 times more potent than tirandamycin. The substituents at the 1 and 5 positions of the tetramic acid as present in streptolydigin are thus not essential for the interaction of the inhibitor with RNA polymerase, but impart a strong potentiating effect. 
